Email

26:I[56264,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js","/_next/static/chunks/2tie5rqwdsi89.js","/_next/static/chunks/2dnipz2c0692b.js","/_next/static/chunks/1mf5iq195c2sn.js","/_next/static/chunks/03wn0-bzh3abk.js","/_next/static/chunks/0_02m0ghanddv.js"],"GuestHistoryRecorder"] 27:I[3004,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js","/_next/static/chunks/2tie5rqwdsi89.js","/_next/static/chunks/2dnipz2c0692b.js","/_next/static/chunks/1mf5iq195c2sn.js","/_next/static/chunks/03wn0-bzh3abk.js","/_next/static/chunks/0_02m0ghanddv.js"],"EmailPreview"] 2a:I[27201,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js"],"IconMark"] 28:T2050, Email

Hi,

You may have seen us in The New York Times, or me on CNN earlier today with Dr. Connie Lehman, founder and CEO of Clairity, announcing our partnership to bring you the Clairity Breast™ 5-Year Risk Assessment as Breast Cancer Awareness Month begins.

Every family carries a story about breast cancer — or doesn't. And that absence can feel like reassurance.

But here’s the truth: About 85% of breast cancers occur in women with no family history,¹ and about 1 in 8 U.S. women will develop invasive breast cancer in her lifetime.²

Family history matters. It just isn't the whole picture.

Clairity Breast is a new way to understand your future breast cancer risk using a compatible screening mammogram taken in the last 12 months.

It uses FDA-authorized, AI-driven software trained and validated on more than 250,000 mammogram images to identify tissue patterns that go beyond traditional risk factors like age and family history — giving you a risk score your provider can use to help personalize your ongoing screening and risk-reduction plan.^3,4,5

Your mammogram has always helped show what's there today. Now, it can also inform conversations with your healthcare provider about the best screening and risk-reduction options for you.

Same mammogram. More to discuss.

Julia Cheek
Founder & CEO, Everlywell

See if Clairity Breast is right for you →

Julia Cheek knows firsthand how frustrating it can be to seek answers about your health, only to hit walls of cost, complexity, and waiting. That experience drove her to found Everlywell with a simple belief: there has to be a better way. What started as at-home lab testing has grown into a suite of comprehensive health testing options, now including the Clairity Breast 5-Year Risk Assessment — a new way to understand your future breast cancer risk, so you can take informed next steps.

No longer want to receive these emails? Unsubscribe.

Your purchase may be HSA/FSA eligible. Check with your plan administrator. Everlywell is not responsible for contacting your plan administrator on your behalf. Everlywell works with a network of licensed clinicians who review your request and order the test.

Clairity Breast provides an estimate of your future breast cancer risk based on your mammogram images. It does not detect or diagnose cancer, and it is not a substitute for ongoing care with your provider. Full Clairity Breast disclosures are available here.

Eligibility is confirmed after purchase; if your mammogram is not compatible or cannot be retrieved or scored, you will receive a full refund.

¹ 2025 Breastcancer.org, “Breast Cancer Facts and Statistics.”

² US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-1930. Available at uspreventiveservicestaskforce.org

³ Clairity, Inc. "Clairity Becomes the First FDA-Authorized AI Platform for Breast Cancer Prediction, Historic Milestone for Women's Health." BusinessWire, June 2, 2025.

⁴ Lehman CD, Hipp E, Scully M, et al. External validation of discrimination and calibration of an image-only AI model for 5-year breast cancer risk prediction across geographically diverse screening sites. RSNA 2025 Scientific Assembly and Annual Meeting; November 30, 2025; Chicago, IL. Abstract S5-SSBR02-5.

⁵ Morris E, Lehman CD, Miller D, et al. Targeted risk stratification in women under 50 using an image-only AI model: addressing the rise in breast cancer incidence in younger women. RSNA 2025 Scientific Assembly and Annual Meeting; December 2, 2025; Chicago, IL. Abstract #11678.

This email was sent by Everlywell
5209 Burnet Road, Suite 300, Austin, TX 78756

Privacy Notice | Terms of Use

29:T10c0,Email Breast cancer risk: a new look. Hi, You may have seen us in The New York Times, or me on CNN earlier today with Dr. Connie Lehman, founder and CEO of Clairity, announcing our partnership to bring you the Clairity Breast™ 5-Year Risk Assessment as Breast Cancer Awareness Month begins. Every family carries a story about breast cancer — or doesn't. And that absence can feel like reassurance. But here’s the truth: About 85% of breast cancers occur in women with no family history,1 and about 1 in 8 U.S. women will develop invasive breast cancer in her lifetime.2 Family history matters. It just isn't the whole picture. Clairity Breast is a new way to understand your future breast cancer risk using a compatible screening mammogram taken in the last 12 months. It uses FDA-authorized, AI-driven software trained and validated on more than 250,000 mammogram images to identify tissue patterns that go beyond traditional risk factors like age and family history — giving you a risk score your provider can use to help personalize your ongoing screening and risk-reduction plan.3,4,5 Your mammogram has always helped show what's there today. Now, it can also inform conversations with your healthcare provider about the best screening and risk-reduction options for you. Same mammogram. More to discuss. Julia Cheek Founder & CEO, Everlywell See if Clairity Breast is right for you → Julia Cheek knows firsthand how frustrating it can be to seek answers about your health, only to hit walls of cost, complexity, and waiting. That experience drove her to found Everlywell with a simple belief: there has to be a better way. What started as at-home lab testing has grown into a suite of comprehensive health testing options, now including the Clairity Breast 5-Year Risk Assessment — a new way to understand your future breast cancer risk, so you can take informed next steps. No longer want to receive these emails? Unsubscribe . Your purchase may be HSA/FSA eligible. Check with your plan administrator. Everlywell is not responsible for contacting your plan administrator on your behalf. Everlywell works with a network of licensed clinicians who review your request and order the test. Clairity Breast provides an estimate of your future breast cancer risk based on your mammogram images. It does not detect or diagnose cancer, and it is not a substitute for ongoing care with your provider. Full Clairity Breast disclosures are availablehere. Eligibility is confirmed after purchase; if your mammogram is not compatible or cannot be retrieved or scored, you will receive a full refund. ¹ 2025 Breastcancer.org, “Breast Cancer Facts and Statistics.” ² US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-1930. Available at uspreventiveservicestaskforce.org ³ Clairity, Inc. "Clairity Becomes the First FDA-Authorized AI Platform for Breast Cancer Prediction, Historic Milestone for Women's Health." BusinessWire, June 2, 2025. ⁴ Lehman CD, Hipp E, Scully M, et al. External validation of discrimination and calibration of an image-only AI model for 5-year breast cancer risk prediction across geographically diverse screening sites. RSNA 2025 Scientific Assembly and Annual Meeting; November 30, 2025; Chicago, IL. Abstract S5-SSBR02-5. ⁵ Morris E, Lehman CD, Miller D, et al. Targeted risk stratification in women under 50 using an image-only AI model: addressing the rise in breast cancer incidence in younger women. RSNA 2025 Scientific Assembly and Annual Meeting; December 2, 2025; Chicago, IL. Abstract #11678. This email was sent by Everlywell 5209 Burnet Road, Suite 300, Austin, TX 78756 Privacy Notice | Terms of Use 1f:["$","article",null,{"className":"min-w-0 flex-1 overflow-hidden","aria-label":"Family history isn't the whole picture","children":[["$","$L26",null,{"emailId":"7c6543f2-7673-4f87-82c6-3dc009a8133c"}],["$","$L27",null,{"email":{"id":"7c6543f2-7673-4f87-82c6-3dc009a8133c","subject":"Family history isn't the whole picture","previewText":"Email Breast cancer risk: a new look. \nHi,\n\nYou may have seen us in The New York Times, or me on CNN earlier today with \nDr. Connie Lehman, founder and CEO of Clairity, announcing our partnership to \nbring you the Clairity Breast™ 5-Year Risk Assessment as Breast Cancer \nAwareness Month begins.\n\nEve","sentAt":"2026-10-01T17:54:58.000Z","classification":"marketing","imageCount":1,"thumbnailUrl":"https://mailspo-ingest.imraan-243.workers.dev/img/renders/7c6543f2-7673-4f87-82c6-3dc009a8133c.jpg","emailType":"newsletter","typeConfidence":"guess","typeBasis":"no stronger signal","brand":"$24:props:brands:312","bodyHtml":"$28","textBody":"$29","bodyFallback":null}}]]}] a:null f:[["$","title","0",{"children":"Family history isn't the whole picture by EverlyWell | Mailspo"}],["$","meta","1",{"name":"description","content":"Email Breast cancer risk: a new look. \nHi,\n\nYou may have seen us in The New York Times, or me on CNN earlier today with \nDr. Connie Lehman, founder and CEO of C"}],["$","meta","2",{"name":"robots","content":"index, follow"}],["$","link","3",{"rel":"canonical","href":"https://mailspo.com/emails/7c6543f2-7673-4f87-82c6-3dc009a8133c"}],["$","meta","4",{"property":"og:title","content":"Family history isn't the whole picture by EverlyWell | Mailspo"}],["$","meta","5",{"property":"og:description","content":"Email Breast cancer risk: a new look. \nHi,\n\nYou may have seen us in The New York Times, or me on CNN earlier today with \nDr. Connie Lehman, founder and CEO of C"}],["$","meta","6",{"property":"og:url","content":"https://mailspo.com/emails/7c6543f2-7673-4f87-82c6-3dc009a8133c"}],["$","meta","7",{"property":"og:site_name","content":"Mailspo"}],["$","meta","8",{"property":"og:image","content":"https://mailspo-ingest.imraan-243.workers.dev/img/renders/7c6543f2-7673-4f87-82c6-3dc009a8133c.jpg"}],["$","meta","9",{"property":"og:image:alt","content":"EverlyWell email creative: Family history isn't the whole picture"}],["$","meta","10",{"property":"og:type","content":"article"}],["$","meta","11",{"property":"article:published_time","content":"2026-10-01T17:54:58.000Z"}],["$","meta","12",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","13",{"name":"twitter:title","content":"Family history isn't the whole picture by EverlyWell | Mailspo"}],["$","meta","14",{"name":"twitter:description","content":"Email Breast cancer risk: a new look. \nHi,\n\nYou may have seen us in The New York Times, or me on CNN earlier today with \nDr. Connie Lehman, founder and CEO of C"}],["$","meta","15",{"name":"twitter:image","content":"https://mailspo-ingest.imraan-243.workers.dev/img/renders/7c6543f2-7673-4f87-82c6-3dc009a8133c.jpg"}],["$","meta","16",{"name":"twitter:image:alt","content":"EverlyWell email creative: Family history isn't the whole picture"}],["$","link","17",{"rel":"icon","href":"/favicon.ico?favicon.3lxqohtg4uvbd.ico","sizes":"48x48","type":"image/x-icon"}],["$","$L2a","18",{}]]

Search Mailspo